Last reviewed · How we verify
DOXAZOSIN MESYLATE
Doxazosin selectively blocks alpha 1 adrenoceptors, reducing urethral resistance and systemic vascular resistance.
Doxazosin Mesylate is a marketed drug primarily indicated for the treatment of Benign Prostatic Hyperplasia (BPH), with a mechanism that selectively blocks alpha 1 adrenoceptors to reduce urethral and systemic vascular resistance. Its key strength lies in its well-established efficacy and safety profile, supported by its current market presence. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | DOXAZOSIN MESYLATE |
|---|---|
| Target | alpha 1 adrenoceptor |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1990 |
Mechanism of action
Doxazosin works by blocking alpha 1 adrenoceptors, which are found in high density in the prostate and bladder neck. This reduces smooth muscle tone and urethral resistance, alleviating BPH symptoms. It also decreases systemic vascular resistance, lowering blood pressure.
Approved indications
- Benign Prostatic Hyperplasia (BPH)
- Hypertension
Common side effects
- Dizziness
- Somnolence
- Hypotension
- Dyspnoea
- Dry Mouth
- Fatigue
- Oedema
- Dizziness
- Somnolence
- Rhinitis
- Polyuria
- Fatigue / Malaise
Drug interactions
- Strong CYP3A inhibitors
- Phosphodiesterase-5 (PDE-5) inhibitors
Key clinical trials
- Alpha-1 Blockade for Alcohol Use Disorder (AUD) (PHASE2)
- Doxazosin an a1 Antagonist for Alcohol Dependence (EARLY_PHASE1)
- Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism
- Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin (PHASE2)
- Doxazosin and Ramipril in Hypertension (PHASE4)
- Phenoxybenzamine Versus Doxazosin in PCC Patients (PHASE4)
- A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
- Genetics of Hypertension Associated Treatments (GenHAT)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOXAZOSIN MESYLATE CI brief — competitive landscape report
- DOXAZOSIN MESYLATE updates RSS · CI watch RSS